Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin
- 1 October 1999
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 48 (4) , 528-535
- https://doi.org/10.1046/j.1365-2125.1999.00044.x
Abstract
Aims The study aimed to identify the specific human cytochrome P450 (CYP450) enzymes involved in the metabolism of artemisinin. Methods Microsomes from human B-lymphoblastoid cell lines transformed with individual CYP450 cDNAs were investigated for their capacity to metabolize artemisinin. The effect on artemisinin metabolism in human liver microsomes by chemical inhibitors selective for individual forms of CYP450 was investigated. The relative contribution of individual CYP450 isoenzymes to artemisinin metabolism in human liver microsomes was evaluated with a tree-based regression model of artemisinin disappearance rate and specific CYP450 activities. Results The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. Recombinant CYP3A4 was catalytically competent in metabolizing artemisinin, although the rate was 10% of that for recombinant CYP2B6. The tree-based regression model suggested CYP3A4 to be of importance in individuals with low CYP2B6 expression. Even though ketoconazole inhibited artemisinin metabolism in human liver microsomes by 46%, incubation with ketoconazole together with orphenadrine did not increase the inhibition of artemisinin metabolism compared to orphenadrine alone. Troleandomycin failed to inhibit artemisinin metabolism. The rate of artemisinin metabolism in recombinant CYP2A6 was 15% of that for recombinant CYP2B6. The inhibition of artemisinin metabolism in human liver microsomes by 8-methoxypsoralen (a CYP2A6 inhibitor) was 82% but CYP2A6 activity was not included in the regression tree. ConclusionsArtemisinin metabolism in human liver microsomes is mediated primarily by CYP2B6 with probable secondary contribution of CYP3A4 in individuals with low CYP2B6 expression. The contribution of CYP2A6 to artemisinin metabolism is likely of minor importance.Keywords
This publication has 29 references indexed in Scilit:
- Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malariaBritish Journal of Clinical Pharmacology, 1998
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9Xenobiotica, 1995
- Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIPCarcinogenesis: Integrative Cancer Research, 1993
- Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomesBiochemical Pharmacology, 1993
- Mefloquine metabolism by human liver microsomes: Effect of other antimalarial drugsBiochemical Pharmacology, 1992
- Metabolism of antimalarial sesquiterpene lactonesPharmacology & Therapeutics, 1990
- cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liverBiochemistry, 1989
- Qinghaosu (Artemisinin): an Antimalarial Drug from ChinaScience, 1985
- Metabolic fate of Qinghaosu in rats; A new TLC densitometric method for its determination in biological materialEuropean Journal of Drug Metabolism and Pharmacokinetics, 1985